New Company Bets Hundreds Of Millions Of Dollars On A Genetic Strategy To Resurrect A CETP Inhibitor

–But skeptics think CETP inhibitors are a dead end A new company is betting hundreds of millions of dollars that it can snatch victory from the jaws of defeat. Over the last decade no class of drugs has undergone a reversal of fortune as dramatic as the cholesterol ester transfer protein (CETP) inhibitors, the once...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Prevention, Epidemiology & Outcomes CETP dalcetrapib DalCor genetic Source Type: blogs